Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 237

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 237
---
 its in-process
research and development and determined that there were no indicators of impairment.

Basic and Diluted Loss per Share 

Basic loss per share is computed by dividing net
loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per
share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential
common shares if their effect is anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate
basic and diluted shares outstanding due to the Company’s net loss position.

At December 31, 2024, the Company had 7,203,307 potentially issuable shares
of common stock upon the exercise of stock options and 3,944,238 potentially issuable shares of common stock upon the exercise of warrants.

At December 31, 2023, the Company had 5,496,000
potentially issuable shares of common stock upon the exercise of stock options and 45,386 potentially issuable shares of common stock
upon the exercise of warrants.

Revenue Recognition

The Company recognizes revenue when the customer
obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange
for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC Topic 606: (1) identify
contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate
the transaction price to the performance obligations in the contract; and (5) recognize revenues when (or as) the Company satisfies the
performance obligations. The Company records the expenses related to revenue in research and development expense, in the periods such
expenses were incurred.

F-9

The Company records deferred revenues when cash
payments are received or due in advance of performance, including amounts which are refundable.

The Company’s 2024 and 2023 revenue was
from the sale of mesenchymal stromal cells to one customer in the United Kingdom and was recognized when the MSC’s were delivered
to the customer. 

Stock-Based Compensation

The Company utilizes the Black-Scholes option
pricing model to estimate the fair value of stock option awards at the date of grant, which requires the input of highly subjective assumptions,
including expected volatility and expected life. Changes in these inputs and assumptions can materially affect the measure of